cimb-logo

Journal Browser

Journal Browser

New Discoveries and Future Perspectives: Leptin and Obesity

A special issue of Current Issues in Molecular Biology (ISSN 1467-3045). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: closed (31 October 2022) | Viewed by 1584

Special Issue Editors


E-Mail Website
Guest Editor
Centro de Investigación Biomédica en Red-Fisiopatología de la Obesidad y Nutrición (CIBEROBN), 28029 Madrid, Spain
Interests: leptin; adipose tissue; obesity treatment; food intake; brown adipose tissue; obesity induced diet; drug delivery
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
1. Unit of Endocrinology, Diabetes and Metabolism, S. Giovanni Calibita, Fatebenefratelli Hospital, 00186 Rome, Italy
2. Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy
Interests: endocrinology; diabetology; obesity; hypertension; metabolic diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Twenty-five years ago, leptin, a hormone produced and secreted by adipose tissue, was discovered. From its first discovery it was identified as having a key role in the field of obesity, and was also discovered to interact with endocrine organs and physiological processes in the control of food intake and energy balance. However, due to the lack of knowledge and understanding of the molecular mechanisms responsible for its effects, the great therapeutic hopes for the involvement of leptin in the treatment of obesity suddenly vanished. Despite this, the research developed around leptin has made great contributions in the field of obesity. However, in the last few years, significant advances have been evidenced in some of the mechanisms of action responsible for effects on body weight control. All of this has meant a rejuvenated interest in this hormone, and it is believed that one day leptin could lead to much-desired therapy against obesity.

In this Special Issue, we welcome contributions related to any aspect of leptin and obesity. Our hope is that, with reference to the most recent and exciting discoveries in this scientific field, we can provide readers with an idea of the mechanisms by which leptin exerts its effects on body weight regulation, and its physiological relevance.

Dr. Marcos Carreira
Dr. Simona Frontoni
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Issues in Molecular Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Leptin
  • blood–brain barrier
  • central nervous system
  • adipose tissue
  • leptin resistance
  • leptin transport
  • hypothalamus

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

7 pages, 457 KiB  
Article
Association of Netrin 1 with hsCRP in Subjects with Obesity and Recent Diagnosis of Type 2 Diabetes
by Jesús Jonathan Garcia Galindo, Maria G. Ramos-Zavala, Sara Pascoe-Gonzalez, Sandra O. Hernández-González, J. Santiago Delgadillo-Centeno, Fernando Grover-Páez, Alberto Beltrán-Ramírez and Daniel O. Suarez Rico
Curr. Issues Mol. Biol. 2023, 45(1), 134-140; https://doi.org/10.3390/cimb45010010 - 26 Dec 2022
Cited by 1 | Viewed by 1223
Abstract
Netrin 1 (Ntn1) is a cell migration protein with an anti-inflammatory effect, which may play a key role in the pathological development of type 2 diabetes (T2D). In this study, we evaluate the relationships between the serum concentrations of Ntn1, glucose, and high-sensitivity [...] Read more.
Netrin 1 (Ntn1) is a cell migration protein with an anti-inflammatory effect, which may play a key role in the pathological development of type 2 diabetes (T2D). In this study, we evaluate the relationships between the serum concentrations of Ntn1, glucose, and high-sensitivity C-reactive Protein (hsCRP). We carried out a cross-sectional study including 90 individuals divided into three groups (n = 30): healthy subjects, individuals with obesity without glucose alterations, and individuals with newly diagnosed T2D. Serum concentrations of Ntn1 and hs-CRP were determined by enzyme-linked immunosorbent assay (ELISA). The serum concentration of Ntn1 was higher in individuals with newly diagnosed T2D (0.33 ± 0.22 ng/mL), in comparison to healthy subjects and individuals with obesity (0.13 ± 0.06 and 0.15 ± 0.07 ng/mL, respectively). In addition, we observed a positive association between the levels of Ntn1 and hsCRP (rho = 0.443; p < 0.001) as well as with serum glucose (rho = −0.110; p = 0.05). The serum concentration of Ntn1 was higher in individuals with T2D, in comparison with the other groups in this study, and presented a positive correlation with hsCRP. Therefore, Ntn1 can be considered a promising risk biomarker and a potential therapeutic target for T2D. Full article
(This article belongs to the Special Issue New Discoveries and Future Perspectives: Leptin and Obesity)
Show Figures

Figure 1

Back to TopTop